๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia

โœ Scribed by E. Van Den Neste; P. Martiat; P. Mineur; A. Delannoy; C. Doyen; A. Zenebergh; J.-L. Michaux; A. Ferrant

Publisher
Springer
Year
1998
Tongue
English
Weight
148 KB
Volume
76
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Mitoxantrone in relapsed or refractory a
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia
โœ Vredenburgh, James J. ;McLntyre, O. Ross ;Cornwell, Gibbons G. ;Ball, Edward D. ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 266 KB

Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days. If the day fourteen bone marrow showed residual leukemia, a second course was given at the same dose for two days. Eight patient

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
โœ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 89 KB ๐Ÿ‘ 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref